TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05768932: BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: SillaJen, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$5,969,040

Rescue Site Savings

+$3,927,000

Unlock Full NCT05768932 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05768932 Rescue Dossier →